Skip to main content
Erschienen in: Diabetologia 12/2014

01.12.2014 | Research Letter

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

verfasst von: Marko Škrtić, Gary K. Yang, Bruce A. Perkins, Nima Soleymanlou, Yuliya Lytvyn, Maximilian von Eynatten, Hans J. Woerle, Odd Erik Johansen, Uli C. Broedl, Thomas Hach, Melvin Silverman, David Z. I. Cherney

Erschienen in: Diabetologia | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor: Renal hyperfiltration in experimental models of early diabetes is associated with increased intraglomerular pressure, and this condition may promote the development of diabetic nephropathy [1]. Despite the functional characterisation of renal hyperfiltration in animal models of diabetes indicating causal involvement of the afferent arteriole, confirmative data in humans are scarce. This is explained by the fact that direct measurements of human glomerular haemodynamic variables, such as afferent (RA) and efferent (RE) arteriolar resistances and glomerular hydrostatic pressure (PGLO), are technically not feasible. To elucidate mechanisms of renal disease in humans, Gomez et al published formulae derived from animal physiological studies in 1951 to estimate glomerular haemodynamic function by using measured mean arterial blood pressure (MAP), GFR, renal plasma flow, haematocrit and total protein concentrations [2]. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hostetter TH, Rennke HG, Brenner BM (1982) The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72:375–380CrossRefPubMed Hostetter TH, Rennke HG, Brenner BM (1982) The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72:375–380CrossRefPubMed
2.
3.
Zurück zum Zitat Cherney DZI, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587–597CrossRefPubMed Cherney DZI, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587–597CrossRefPubMed
4.
Zurück zum Zitat Cherney DZ, Perkins BA, Soleymanlou N et al (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13:28CrossRefPubMedPubMedCentral Cherney DZ, Perkins BA, Soleymanlou N et al (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13:28CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Perkins BA, Cherney DZ, Partridge H et al (2014) Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37:1480–1483CrossRefPubMed Perkins BA, Cherney DZ, Partridge H et al (2014) Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37:1480–1483CrossRefPubMed
6.
Zurück zum Zitat Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569–2576PubMed Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569–2576PubMed
7.
Zurück zum Zitat Luik PT, Hoogenberg K, van Der Kleij FG et al (2002) Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric type I diabetes mellitus. Diabetologia 45:535–541CrossRefPubMed Luik PT, Hoogenberg K, van Der Kleij FG et al (2002) Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric type I diabetes mellitus. Diabetologia 45:535–541CrossRefPubMed
8.
Zurück zum Zitat Investigators O, Yusuf S, Teo KK et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559CrossRef Investigators O, Yusuf S, Teo KK et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559CrossRef
9.
Zurück zum Zitat Parving H-H, Brenner BM, McMurray JJV et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204–2213CrossRefPubMed Parving H-H, Brenner BM, McMurray JJV et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204–2213CrossRefPubMed
10.
Zurück zum Zitat Fried LF, Emanuele N, Zhang JH et al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369:1892–1903CrossRefPubMed Fried LF, Emanuele N, Zhang JH et al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369:1892–1903CrossRefPubMed
Metadaten
Titel
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
verfasst von
Marko Škrtić
Gary K. Yang
Bruce A. Perkins
Nima Soleymanlou
Yuliya Lytvyn
Maximilian von Eynatten
Hans J. Woerle
Odd Erik Johansen
Uli C. Broedl
Thomas Hach
Melvin Silverman
David Z. I. Cherney
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 12/2014
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3396-4

Weitere Artikel der Ausgabe 12/2014

Diabetologia 12/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.